Aimmune Therapeutics (AIMT) Reaches New 52-Week Low at $24.24

Shares of Aimmune Therapeutics Inc (NASDAQ:AIMT) reached a new 52-week low on Wednesday . The stock traded as low as $24.24 and last traded at $24.65, with a volume of 6487 shares traded. The stock had previously closed at $25.18.

Several analysts recently weighed in on AIMT shares. ValuEngine downgraded Aimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 7th. Credit Suisse Group set a $40.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, August 13th. Cantor Fitzgerald set a $62.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Monday, October 15th. Roth Capital set a $80.00 price target on Aimmune Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 9th. Finally, Wedbush started coverage on Aimmune Therapeutics in a research note on Wednesday, October 17th. They issued a “buy” rating and a $72.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $51.50.

The company has a market cap of $1.42 billion, a P/E ratio of -9.28 and a beta of -0.10.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Thursday, November 8th. The biotechnology company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.03. Sell-side analysts expect that Aimmune Therapeutics Inc will post -3.65 earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, insider Jayson Donald Alexander Dallas bought 3,650 shares of the business’s stock in a transaction on Monday, November 19th. The shares were acquired at an average cost of $27.56 per share, for a total transaction of $100,594.00. Following the purchase, the insider now owns 63,600 shares in the company, valued at approximately $1,752,816. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 24.56% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of AIMT. Legal & General Group Plc boosted its stake in Aimmune Therapeutics by 55.2% during the 1st quarter. Legal & General Group Plc now owns 14,102 shares of the biotechnology company’s stock valued at $449,000 after purchasing an additional 5,015 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Aimmune Therapeutics by 4,412.4% in the 1st quarter. Royal Bank of Canada now owns 17,463 shares of the biotechnology company’s stock worth $555,000 after buying an additional 17,076 shares during the last quarter. Fred Alger Management Inc. purchased a new position in shares of Aimmune Therapeutics in the 2nd quarter worth $269,000. Janney Montgomery Scott LLC boosted its stake in shares of Aimmune Therapeutics by 27.8% in the 2nd quarter. Janney Montgomery Scott LLC now owns 14,720 shares of the biotechnology company’s stock worth $396,000 after buying an additional 3,200 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in shares of Aimmune Therapeutics by 16.6% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 260,435 shares of the biotechnology company’s stock worth $7,003,000 after buying an additional 37,053 shares during the last quarter. Institutional investors and hedge funds own 76.92% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by WKRB News and is the property of of WKRB News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/11/23/aimmune-therapeutics-aimt-reaches-new-52-week-low-at-24-24.html.

About Aimmune Therapeutics (NASDAQ:AIMT)

Aimmune Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy.

Further Reading: How is a Moving Average Calculated?

Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply